We work at the decisions where scientific uncertainty becomes development risk.

Questions addressed

• Is the biological hypothesis sufficiently differentiated?
• Is the target relevant to pain, structure or both?
• Is local or systemic administration justified?
• What evidence is missing before clinical development?
• Is the selected indication the most credible entry point?
• What would make the programme non-viable?

Deliverables may include

• Integrated asset assessment
• Target product profile
• Competitive landscape
• Evidence-gap map
• Development roadmap
• Go/no-go framework
• Critical experiments and analyses

Questions addressed

• Which patients express the relevant biology?
• At what disease stage is the mechanism actionable?
• Which clinical and structural features should be required?
• Which competing pain mechanisms should be excluded?
• Can the proposed population be recruited at scale?
• Will the target population be identifiable after approval?

Deliverables may include

• Phenotype and mechanism map
• Theratype hypothesis
• Enrichment strategy
• Eligibility criteria
• Subgroup plan
• Biomarker and imaging selection
• Recruitment-feasibility analysis

Questions addressed

• What must the next trial prove?
• Is the study a proof-of-mechanism, proof-of-concept or confirmatory trial?
• Which endpoint should be primary?
• How should pain and structural outcomes be integrated?
• How should rescue medication and intercurrent events be handled?
• What duration is biologically and regulatorily credible?

Deliverables may include

• Clinical development plan
• Protocol synopsis
• Protocol review
• Endpoint hierarchy
• Estimand framework
• Statistical design
• Imaging charter strategy
• Biomarker plan
• Go/no-go criteria

Questions addressed

• What claim is supportable?
• How should symptom and structure be positioned?
• What evidence will FDA or EMA expect?
• Is a biomarker sufficiently mature for the intended context of use?
• How should an advanced therapy be classified and followed?
• What questions should be resolved through scientific advice?

Deliverables may include

• Regulatory gap analysis
• US and European strategy
• Pre-IND preparation
• Scientific advice preparation
• Briefing documents
• Question strategy
• Meeting rehearsal
• Response review
• End-of-phase planning

Questions addressed

• Was the mechanism wrong or was the trial unable to test it?
• Did population heterogeneity dilute the effect?
• Were the endpoint and timing aligned with the mechanism?
• Was a biological or structural signal missed?
• Is a subgroup finding credible and reproducible?
• Is another dose, population or indication defensible?

Deliverables may include

• Integrated failure analysis
• Data review
• Subgroup credibility assessment
• Biomarker and imaging reassessment
• Redesign scenarios
• Regulatory recovery strategy
• Repositioning options
• Stop, continue or pivot recommendation

Questions addressed

• What evidence will materially increase asset value?
• How differentiated is the future product profile?
• What would a pharmaceutical partner consider credible?
• What is the realistic place in the treatment pathway?
• What evidence will payers and prescribers require?
• Which milestone should be reached before partnering?

Deliverables may include

• Value-creation plan
• Partnering narrative
• Investor scientific story
• Market segmentation
• Treatment-pathway analysis
• Competitive positioning
• Evidence-generation priorities
• Partner due diligence preparation